John Matthew Mauro

Array ( [id] => 19675868 [patent_doc_number] => 12187718 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-01-07 [patent_title] => 1-cyclopropyl-6-fluoro-7-(4-((5-(4-methoxybenzylideneamino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid as an anti-inflammatory and anticancer compound [patent_app_type] => utility [patent_app_number] => 18/807253 [patent_app_country] => US [patent_app_date] => 2024-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 4271 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18807253 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19614860 [patent_doc_number] => 20240400540 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-05 [patent_title] => PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/804443 [patent_app_country] => US [patent_app_date] => 2024-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33971 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18804443 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19700036 [patent_doc_number] => 12194034 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-14 [patent_title] => Neutrophil exocytosis inhibitors [patent_app_type] => utility [patent_app_number] => 18/617768 [patent_app_country] => US [patent_app_date] => 2024-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 16 [patent_no_of_words] => 28435 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1355 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18617768 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19297548 [patent_doc_number] => 20240226113 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-11 [patent_title] => HETEROCYCLIC COMPOUNDS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/439666 [patent_app_country] => US [patent_app_date] => 2024-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 151669 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 696 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18439666 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19043524 [patent_doc_number] => 11932608 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-03-19 [patent_title] => 4-((2-(2-(2-(4-hydroxyphenyl)-4,5-diphenyl-1H-imidazol-1-yl)acetyl)hydrazono)methyl)benzoic acid as an anticancer compound [patent_app_type] => utility [patent_app_number] => 18/518285 [patent_app_country] => US [patent_app_date] => 2023-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 3558 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18518285 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19060091 [patent_doc_number] => 11939299 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-03-26 [patent_title] => 4-((2-(2-(2-(4-methoxyphenyl)-4,5-diphenyl-1H-imidazol-1-yl)acetyl)hydrazono)methyl)benzoic acid as an anti-cancer compound [patent_app_type] => utility [patent_app_number] => 18/512463 [patent_app_country] => US [patent_app_date] => 2023-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 3581 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18512463 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19105776 [patent_doc_number] => 11958857 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-04-16 [patent_title] => 5-(1H-indol-3-yl)-1,3-substitutedpyrimido[4,5-d]pyrimidine-2,4,7(1H,3H,8H)-trione as anticancer agents [patent_app_type] => utility [patent_app_number] => 18/388901 [patent_app_country] => US [patent_app_date] => 2023-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5764 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18388901 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19060118 [patent_doc_number] => 11939326 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-03-26 [patent_title] => 7-(4-((5-(benzylideneamino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid as an anti-inflammatory and anticancer compound [patent_app_type] => utility [patent_app_number] => 18/388756 [patent_app_country] => US [patent_app_date] => 2023-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 4248 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18388756 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19050817 [patent_doc_number] => 20240092786 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/386777 [patent_app_country] => US [patent_app_date] => 2023-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16312 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18386777 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18895178 [patent_doc_number] => 20240010663 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => PSILOCYBIN AND O-ACETYLPSILOCIN, SALTS AND SOLID STATE FORMS THEREOF [patent_app_type] => utility [patent_app_number] => 18/468583 [patent_app_country] => US [patent_app_date] => 2023-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 175537 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18468583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19027254 [patent_doc_number] => 11926601 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-03-12 [patent_title] => 5-spiro 9,10-dihydroanthracene derivative of imidazolidine-2,4-dione as an anticancer agent [patent_app_type] => utility [patent_app_number] => 18/239233 [patent_app_country] => US [patent_app_date] => 2023-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 4228 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18239233 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18815946 [patent_doc_number] => 20230390285 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => Lurbinectedin Composition and Methods Making the Same [patent_app_type] => utility [patent_app_number] => 18/448144 [patent_app_country] => US [patent_app_date] => 2023-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50899 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18448144 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18953545 [patent_doc_number] => 20240041872 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => STABLE LURBINECTEDIN COMPOSITION [patent_app_type] => utility [patent_app_number] => 18/448097 [patent_app_country] => US [patent_app_date] => 2023-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50850 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18448097 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19013000 [patent_doc_number] => 11919915 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-05 [patent_title] => Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations [patent_app_type] => utility [patent_app_number] => 18/214831 [patent_app_country] => US [patent_app_date] => 2023-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 167491 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18214831 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18725770 [patent_doc_number] => 20230339981 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => KRAS G12D MODULATING COMPOUNDS [patent_app_type] => utility [patent_app_number] => 18/334924 [patent_app_country] => US [patent_app_date] => 2023-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 108594 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18334924 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18784695 [patent_doc_number] => 20230372301 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => TREATMENTS WITH NIROGACESTAT [patent_app_type] => utility [patent_app_number] => 18/320591 [patent_app_country] => US [patent_app_date] => 2023-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26217 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18320591 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18643252 [patent_doc_number] => 11767312 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-26 [patent_title] => Phthalazinone compound, and preparation method therefor and medical use thereof [patent_app_type] => utility [patent_app_number] => 18/131309 [patent_app_country] => US [patent_app_date] => 2023-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33950 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18131309 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19083076 [patent_doc_number] => 20240109877 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE [patent_app_type] => utility [patent_app_number] => 18/187489 [patent_app_country] => US [patent_app_date] => 2023-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21988 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 5 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18187489 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18733406 [patent_doc_number] => 11802129 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2023-10-31 [patent_title] => Pyrido[3,4-b]indol-1-one compounds as anticancer agents [patent_app_type] => utility [patent_app_number] => 18/123748 [patent_app_country] => US [patent_app_date] => 2023-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9382 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18123748 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18801277 [patent_doc_number] => 11834428 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-05 [patent_title] => Dihydromyricetin nanocrystals and preparation method and application thereof [patent_app_type] => utility [patent_app_number] => 18/116204 [patent_app_country] => US [patent_app_date] => 2023-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 3802 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18116204 [rel_patent_id] =>[rel_patent_doc_number] =>)